Metabolic Research, Inc.
OTC Bulletin Board : MTBR

Metabolic Research, Inc.

March 29, 2007 08:36 ET

Metabolic Research, Inc. Appoints Dr. Robert Shorr as Chairman of Newly-Formed Scientific Advisory Board

MONTGOMERY, TEXAS--(CCNMatthews - March 29, 2007) - Metabolic Research, Inc. (OTCBB:MTBR) announced today that the company has appointed Dr. Robert Shorr, Ph.D. to the position of Chairman of the Company's newly-formed Scientific Advisory Board. The Scientific Advisory Board functions as an expert "guiding body" which continually assesses the Company's technologies and potential technological breakthroughs weighed against market potential, cost, and return on investment.

Dr. Shorr is currently CEO of Cornerstone Pharmaceuticals, a private company focused on solid tumor chemotherapy. Previously, he has served as Vice President Science and Technology at Enzon Inc., where he worked with Schering Plough to develop PEG INTRON A. Dr Shorr was also Chief Scientist for United Therapeutics and Director of Business Development for the State University of New York at Stony Brook Center for Biotechnology. He has also served as Associate Director for Molecular Pharmacology at SmithKline and French. Dr. Shorr received his Ph.D. and D.I.C. in Biochemistry from the University of London Imperial College of Science and Technology, London, England and his Rabbinic ordination from Yeshivat Pirchei Shoshanim, Lakewood NJ and Jerusalem Israel. Dr. Shorr completed his postdoctoral training at the Howard Hughes Medical Institute, Duke University Medical Center, Durham, North Carolina.

"Dr. Shorr is an experienced entrepreneur, drug developer and investor. His many years of valuable experience in the research, development and marketing of cutting-edge medical and biomedical technologies should prove invaluable to Metabolic Research as we forge ahead with our development of pharmaceutical-grade non-synthetic pharmaceuticals aimed to safely and effectively treat arthritis, heart disease and metabolic and inflammatory diseases," says Nick Montesano, Chief Executive Officer of Metabolic Research, Inc.

About Metabolic Research, Inc.

Metabolic Research, Inc. intends to develop a new form of pharmaceutical-grade non-synthetic pharmaceuticals to safely and effectively treat inflammatory diseases. Metabolic Research's proprietary process is based on "growing" drugs by using natural metabolic processes of plants or fungus rather than chemical synthesis used by traditional pharmaceutical companies. For more information, please visit the company's website at:

This press release may include "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations reflected in such forward-looking statements will prove to have been correct. The Company's actual results could differ materially from those anticipated in the forward-looking statements. The Company refers you to the cautionary statements and risk factors set forth in the documents it files with the Securities and Exchange Commission. Neither the Company or Phoenix IR Associates is under any obligation (and expressly disclaims any obligation) to update or alter its forward-looking statements, whether as a result of new information, future events, or otherwise.

Contact Information